{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:02:32Z","timestamp":1769742152515,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jaad.2014.05.073","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T20:00:09Z","timestamp":1410811209000},"page":"832-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea"],"prefix":"10.1016","volume":"71","author":[{"given":"Leah A.","family":"Swanson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Warshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jaad.2014.05.073_bib1","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","article-title":"Management of facial erythema of rosacea: what is the role of topical \u03b1-adrenergic receptor agonist therapy?","volume":"69","author":"Del Rosso","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.073_bib2","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment\u00a0of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.05.073_bib3","unstructured":"Galderma Laboratories LP. Mirvaso (brimonidine) 0.33% topical gel product information. 2013. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204708lbl.pdf."},{"key":"10.1016\/j.jaad.2014.05.073_bib4","unstructured":"Allergan Inc. Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% product information. 2013. Available at: www.allergan.com\/assets\/pdf\/alphaganp_pi.pdf."},{"key":"10.1016\/j.jaad.2014.05.073_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00061198-200404000-00014","article-title":"Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy","volume":"13","author":"Manni","year":"2004","journal-title":"J Glaucoma"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214016569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214016569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:28Z","timestamp":1759271608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214016569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0190962214016569"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.05.073","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.05.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.06.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}